Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

被引：0
|
作者：
Curtis, Jeffrey R. [1 ]
Wollenhaupt, Juergen [2 ]
Chatzidionysiou, Katerina [3 ]
Tas, Sander W. [4 ]
Wang, Lisy [5 ]
Shi, Harry [6 ]
Montoro, Maria [7 ]
Neregard, Petra [8 ]
Dahl, Palle [9 ]
Tsekouras, Vassilis [10 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Hamburg, Schon Klin Hamburg Eilbek Teaching Hosp, Hamburg, Germany
[3] Karolinska Inst, Div Rheumatol, Dept Med, Stockholm, Sweden
[4] Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer Inc, Madrid, Spain
[8] Pfizer Inc, Stochholm, Sweden
[9] Pfizer Inc, Ballerup, Denmark
[10] Pfizer Inc, Athens, Greece
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1519
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study
    Taylor, P.
    Genovese, M.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    Lundmark, J.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 59 - 59
  • [42] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, Peter
    Genovese, Mark
    Keystone, Ed
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A31 - A31
  • [43] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, P.
    Genovese, M. C.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 66
  • [44] Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
    Fleischmann, Roy
    Wollenhaupt, Juergen
    Cohen, Stanley
    Weinblatt, Michael
    Wang, Lisy
    Fan, Haiyun
    Andrews, John
    Takiya, Liza
    Bananis, Eustratios
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [45] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
    Lichtenstein, G. R.
    Loftus, E. V., Jr.
    Wei, S. C.
    Damiao, A. O.
    Judd, D.
    Lawendy, N.
    Chan, G.
    Zhang, H.
    Wang, W.
    Thorpe, A. J.
    Bloom, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
  • [46] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Cohen, Stanley
    Pablos, Jose L.
    Pavelka, Karel
    Mueller, Gerard Anton
    Matsumoto, Alan
    Kivitz, Alan
    Wang, Hui
    Krishnan, Eswar
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [47] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Stanley Cohen
    Jose L. Pablos
    Karel Pavelka
    Gerard Anton Müller
    Alan Matsumoto
    Alan Kivitz
    Hui Wang
    Eswar Krishnan
    [J]. Arthritis Research & Therapy, 21
  • [48] Laboratory Parameters Related to Monitoring in Patients With Ulcerative Colitis Treated With Tofacitinib for up to 3 Years in the OCTAVE Open-Label, Long-Term Extension Study
    Melmed, Gil Y.
    Chang, Shannon
    Kulisek, Nicole
    Fan, Haiyun
    Lawendy, Nervin
    Maller, Eric
    Soonasra, Arif
    Irving, Peter M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S431 - S431
  • [49] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Ruediger B. Mueller
    Hendrik Schulze-Koops
    Daniel E. Furst
    Stanley B.  Cohen
    Kenneth Kwok
    Lisy Wang
    Tim Killeen
    Johannes von Kempis
    [J]. Clinical Rheumatology, 2022, 41 : 1045 - 1055
  • [50] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Mueller, Ruediger B.
    Schulze-Koops, Hendrik
    Furst, Daniel E.
    Cohen, Stanley B.
    Kwok, Kenneth
    Wang, Lisy
    Killeen, Tim
    von Kempis, Johannes
    [J]. CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055
12345